Indegene reports revenue and profit growth for September 2025 quarter

Related-party transactionsResults View source PDF Explain this filing

INDGN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.7%Reaction day

₹552.65

prior close

₹555.85

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.6%-2.1% vs market

Healthcare Services peers, median of 50sector · industry level-0.3%-2.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Smallcap 250 and 2.4 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-2.0

15m

-2.7

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.7-0.6-2.1-0.3-2.4

Next day

-3.0+0.1-3.1-0.4-2.7

-2.5-0.5-2.0-0.1-2.4

-3.9-2.0-1.9-1.6-2.3

-5.4-2.2-3.2-1.8-3.6

-6.6-2.3-4.4-2.5-4.1

-7.9-1.7-6.2-1.7-6.2

15d

-7.0-4.6-2.4-3.7-3.3

-4.4-3.7-0.7-5.1+0.6

-5.9-4.2-1.7-6.4+0.5

-11.3-10.9-0.4-16.3+5.0

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 50Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the September 2025 quarter, consolidated revenue was Rs 804.2 crore, up 17.1% year on year, and profit after tax was Rs 102.1 crore, up 11.3%. First-half revenue rose 14.8% to Rs 1,565 crore and profit after tax rose 21.8% to Rs 218.5 crore. The auditor gave an unmodified review. The board also approved the BioPhann acquisition for USD 104 million and Warn and Co for about GBP 3 million, and EUR 8.5 million for the Ireland subsidiary.

Likely market impact

Revenue and profit growth support sentiment, but narrower margins, acquisition spending and unresolved US litigation could weigh on the stock.

By the numbersConsolidated · Q2 FY26 vs Q2 FY25

	Q2 FY26	Q2 FY25	Change
Revenue	₹804.2 Cr	₹686.8 Cr	+17.1%
Operating profit	₹113.4 Cr	₹102.7 Cr	+10.4%
Profit after tax	₹102.1 Cr	₹91.70 Cr	+11.3%
EBITDA margin	17.5%	18.4%	−0.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.